ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

被引：0
|
作者：
Jong-Mu Sun
Ji-Youn Sung
Se Hoon Park
Ghee Young Kwon
Byong Chang Jeong
Seong Il Seo
Seong Soo Jeon
Hyun Moo Lee
Jisuk Jo
Han Yong Choi
Ho Yeong Lim
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Sungkyunkwan University School of Medicine,Oncology, Department of Medicine, Samsung Medical Center
[3] Sungkyunkwan University School of Medicine,Department of Pathology, Samsung Medical Center
[4] Cancer Research Institute,Department of Urology, Samsung Medical Center
[5] Research Institute for Future Medicine,undefined
[6] Samsung Medical Center,undefined
来源：
BMC Cancer | / 12卷
关键词：
Bladder Cancer; Adjuvant Chemotherapy; Transitional Cell Carcinoma; ERCC1 Expression; Nucleotide Excision Repair Pathway;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Olaussen, Ken A.
    Dunant, Ariane
    Fouret, Pierre
    Brambilla, Elisabeth
    Andre, Fabrice
    Haddad, Vincent
    Taranchon, Estelle
    Filipits, Martin
    Pirker, Robert
    Popper, Helmut H.
    Stahel, Rolf
    Sabatier, Laure
    Pignon, Jean-Pierre
    Tursz, Thomas
    Le Chevalier, Thierry
    Soria, Jean-Charles
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (10): : 983 - 991
  • [42] C-Met and ERCC1 are Prognostic in Patients Receiving Neoadjuvant or Adjuvant Chemoradiation for Pancreatic Cancer
    Cuneo, K. C.
    Morgan, M. A.
    Zalupski, M. M.
    Greenson, J. K.
    Schipper, M.
    Griffith, K. A.
    Ben-Josef, E.
    Lawrence, T. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S156 - S156
  • [43] Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis
    Simon, George R.
    Schell, Michael J.
    Begum, Mubeena
    Kim, Jongphil
    Chiappori, Alberto
    Haura, Eric
    Antonia, Scott
    Bepler, Gerold
    CANCER, 2012, 118 (09) : 2525 - 2531
  • [44] ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
    Li, Yangkai
    Liu, Zhensheng
    Liu, Hongliang
    Wang, Li-E
    Tan, Dongfeng
    Ajani, Jaffer A.
    Wei, Qing-Yi
    PLOS ONE, 2013, 8 (09):
  • [45] Testing for biomarker driven therapy (ERCC1 and EGFR)
    Dancey, Janet Ellen
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S172 - S173
  • [46] A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy
    Kawashima, Atsunari
    Takayama, Hitoshi
    Tsujimura, Akira
    ADVANCES IN UROLOGY, 2012, 2012
  • [47] Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer
    Zhou, Lin
    Xu, Le
    Chen, Lingli
    Fu, Qiang
    Liu, Zheng
    Chang, Yuan
    Lin, Zongming
    Xu, Jiejie
    ONCOIMMUNOLOGY, 2017, 6 (04):
  • [48] Evaluation of ERCC1 and RRM1 as prognostic biomarkers in urothelial cancer (UC) treated with adjuvant platinum and gemcitabine chemotherapy.
    Harshman, Lauren Christine
    Bepler, Gerold
    Quinn, David I.
    McKenney, Jesse
    Hawes, Debra
    Simon, Noah
    Srinivas, Sandy
    Dorff, Tanya B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
    Li, Hui-Yan
    Ge, Xin
    Huang, Guang-Ming
    Li, Kai-Yu
    Zhao, Jing-Quan
    Yu, Xi-Miao
    Bi, Wen-Si
    Wang, Yu-Lin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (07) : 3465 - 3469
  • [50] Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer
    Liu, L.
    Li, C. H.
    Jin, T. F.
    Xu, D. Y.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (04) : 8722 - 8728
12345